Cencora

(New York Stock Exchange)

Top News rankings and signal summaries are processed using AI and may contain errors.

21
Somewhat Bullish +45

Cencora (COR) Raised Guidance and Bought Back $1B. What’s the Catch?

AI-generated analysis

Cencora (NYSE: COR) reported a strong fiscal third quarter with revenue rising 5.1% to $84.8 billion and adjusted earnings per share climbing 12.0% to $4.48. Management raised its full-year adjusted EPS outlook to between $17.75 and $17.95, while the company accelerated its capital return program...

Bullish Signals

  • EPS guidance raised to $17.75-$17.95.
  • Completed $1B stock buyback in one quarter.
  • Gross margin expanded 61 bps to 4.16%.
  • International operating income up 20.8%.
  • US operating income grew 15.9%.

Bearish Signals

  • Operating expenses rose 26.8% amid OneOncology integration costs.
  • Net interest expense increased $58.9M, weighing on profitability.
  • Sales mix shift to lower-margin GLP-1 drugs reduces profit.
  • Lost oncology customer in 2025 impacted US revenue.
  • Lower manufacturer prices suppress domestic revenue growth.
22
Slightly Bullish +15

California Public Employees Retirement System Reduces Stake in Cencora ...

AI-generated analysis

California Public Employees Retirement System (CalPERS) reduced its stake in Cencora, Inc. (NYSE:COR) by 12.5% during the first quarter, selling 61,988 shares to hold approximately 432,701 shares valued at $135.9 million. While CalPERS decreased its position, several other major institutional investors increased their holdings in...

Bullish Signals

  • Major investors like Vanguard and JPMorgan Chase increased stakes.
  • T. Rowe Price added 4 million shares, up 160.1%.
  • $2.0 billion stock repurchase program announced by management.
  • Revenue grew 3.9% year-over-year despite missing earnings estimates.
  • Director Lauren M. Tyler ownership rose 14.44%.

Bearish Signals

  • Missed Q1 EPS by $0.07 and revenue by $2.7 billion.
  • Wells Fargo lowered target from $429 to $331.
  • Barclays cut target from $425 to $350.
  • CalPERS reduced holdings by 12.5% in Q1.
23
Slightly Bullish +15

Allspring Global Investments Holdings LLC Grows Stock Holdings in ...

AI-generated analysis

Allspring Global Investments Holdings LLC increased its stake in Cencora, Inc. (NYSE:COR) by 7.8% during the first quarter, acquiring an additional 29,983 shares to hold a total of 413,051 shares valued at $131.21 million. This represents a 0.21% ownership stake in the company. Several other...

Bullish Signals

  • Archer Investment Corp increased holdings by 134.3% in Q4.
  • Cencora approved a $2.00 billion share repurchase program.
  • Quarterly dividend of $0.60 with 0.8% annualized yield.
  • Director Lauren M. Tyler ownership increased by 14.44%.
  • Revenue grew 3.9% year-over-year to $78.36 billion.

Bearish Signals

  • EPS missed estimates at $4.75 vs $4.82 consensus.
  • Revenue fell short at $78.36B vs $81.09B expected.
  • Major analysts cut targets: Baird to $339, Citi to $355.
  • Wells Fargo lowered target from $429 to $331.
24
Slightly Bullish +25

Bleakley Financial Group LLC Has $5.35 Million Stake in Cencora, Inc ...

AI-generated analysis

Bleakley Financial Group LLC reduced its stake in Cencora, Inc. (NYSE:COR) by 39.4% in the first quarter, selling 11,082 shares to hold a remaining position of 17,020 shares valued at approximately $5.35 million. This move contrasts with several other institutional investors who increased their holdings...

Bullish Signals

  • Cencora initiates $2.0B stock repurchase plan.
  • Revenue grew 3.9% YoY to $78.36B.
  • Analysts rate 'Moderate Buy' with $367.75 target.
  • Director Tyler increased ownership by 14.44%.

Bearish Signals

  • Revenue of $78.36B missed analyst consensus of $81.09B.
  • Stock trades below 200-day moving average of $318.31.
  • Liquidity concerns with current ratio of 0.95 and quick ratio of 0.59.
25
Bullish +65

Cencora, Inc. (COR) Expands Into Retina Services Business in $1.1B Deal

AI-generated analysis

Cencora, Inc. (NYSE: COR) announced a strategic acquisition of EyeSouth's partner's retina business for $1.1 billion, marking a significant expansion into the specialty pharmaceutical services sector. The deal is financed through existing credit facilities and cash reserves, with analysts from UBS and Evercore ISI reiterating...

Bullish Signals

  • $1.1B acquisition accretive to EPS within 12 months.
  • UBS and Evercore ISI rate Buy with $410-$420 targets.
  • Expands into high-growth specialty segment diversifying revenue.
  • Existing retina platform generated $600M revenue and $75M EBITDA in 2022.
  • Unified platform integration expected to generate significant cost synergies.